Cartalax 20mg Research Peptide

Cartalax 20mg is a synthetic research peptide classified among the Khavinson peptides, a group of short peptides studied for their potential role in cellular regulation and tissue-specific signaling. Cartalax 20mg is derived from the amino acid sequence Alanine–Glutamate–Aspartate, corresponding to a fragment of the alpha-1 chain of type XI collagen. It is supplied as a lyophilized powder with a reported purity greater than 99%, intended exclusively for laboratory research applications.

What Is Cartalax 20mg?

Cartalax, also known as AED peptide or T-31 peptide, is a short synthetic tripeptide originally identified in kidney-derived polypeptide extracts and later synthesized for research purposes. Within experimental settings, Cartalax 20mg has been investigated as a bioregulatory peptide, with research interest centered on cellular aging markers, connective tissue signaling, and cartilage-associated biological processes.

Cartalax 20mg is not approved for human or animal use and remains an experimental compound.

Research Background

Research into Cartalax 20mg has focused on its potential involvement in biological processes associated with:

• Fibroblast proliferation models

• Cellular lifespan and senescence markers

• Tissue regeneration signaling pathways

• Inflammatory response modulation in preclinical models

Studies exploring Khavinson peptides often examine their ability to influence gene expression and cellular activity in a tissue-specific manner. Findings related to Cartalax are limited to in vitro and animal research and have not been validated in clinical trials.

Mechanisms of Research Interest

Within laboratory studies, Cartalax 20mg has been examined for its potential influence on several cellular markers and processes:

Cell Proliferation

Research suggests Cartalax may be associated with increased expression of Ki-67, a marker commonly used to assess cellular division and proliferation in fibroblast models.

Cell Regeneration Signaling

Cartalax has been studied for its possible relationship with CD98hc expression, a protein involved in cellular vitality and regenerative signaling pathways.

Apoptosis Modulation

Experimental findings have explored whether Cartalax may influence apoptotic signaling, including potential modulation of caspase-3 activity, a key enzyme involved in programmed cell death.

Cartilage and Connective Tissue Research

Cartalax 20mg has been investigated in research models related to cartilage biology and connective tissue signaling, particularly in studies examining osteoarthritis-associated cellular markers.

These mechanisms remain theoretical and experimental and should not be interpreted as established biological outcomes.

Molecular and Chemical Information

• Product Name: Cartalax 20mg

• Form: Lyophilized powder

• Purity: Greater than 99%

• Molecular Formula: C12H19N3O8

• Molecular Weight: 333.29 g/mol

• Amino Acid Sequence: Alanine–Glutamate–Aspartate

• Alternate Names: AED, T-31, SCHEMBL5324601

Research Applications

Cartalax 20mg may be utilized by qualified researchers in laboratory studies involving:

• Cellular aging and senescence models

• Fibroblast lifespan research

• Connective tissue and cartilage biology

• Bioregulatory peptide investigations

All applications must remain within controlled research environments.

Regulatory Status and Use Disclaimer

• For research use only

• Not approved by the Food and Drug Administration

• Not intended for human or veterinary use

• Not intended to diagnose, treat, cure, or prevent any disease

• No established clinical safety or efficacy data